An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape)
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Pasireotide (Primary)
- Indications Cushing syndrome
- Focus Adverse reactions; Expanded access
- Acronyms Seascape
- Sponsors Novartis; Novartis Pharmaceuticals
- 28 Feb 2017 Status changed from active, no longer recruiting to completed.
- 04 Nov 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
- 22 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2016.